How does tigecycline's patent extension affect generic production?

Why do companies file for patent term extensions on tigecycline?

Patent term extensions add up to five years beyond the standard 20-year term to compensate for regulatory review delays at the FDA. Tigecycline's original compound patent, filed in 1994, received a 1,121-day extension that shifted its expiry from June 2013 to July 2016.

What happens to generic production after a patent extension takes effect?

Generic manufacturers must wait until the extended patent expires before launching products that use the basic compound. Any attempt to enter the market earlier would expose them to infringement suits and injunctions. After July 2016, multiple generic approvals followed, lowering prices significantly.

How does this extension interact with other protections like exclusivity and pediatric extensions?

The 1,121-day extension overlapped with five-year new chemical entity exclusivity and possible six-month pediatric exclusivity. Stacking these protections delayed full generic competition until well beyond the core patent life. Overlapping rights mean generics cannot challenge or bypass them easily.

Can generics launch at risk before the extended patent expires?

At-risk launches expose companies to treble damages if they lose litigation. Tigecycline generics faced active litigation around 2013–2016, preventing early entry. Companies usually avoid at-risk entry when extensions are already granted.

When does tigecycline's extended patent actually expire?

The compound patent with its 1,112-day extension expired July 2016. Data exclusivity periods and any remaining method-of-use or formulation patents could still block generic sales in narrower scopes.

Who makes generic tigecycline today?

Several manufacturers, including Pfizer's own authorized generic and independent firms like Accord Healthcare, entered after July 2016. Price drops of 70–80% occurred once multiple generics competed.

How does tigecycline's patent history affect current pricing?

Post-extension generics drove substantial price reductions. Current average wholesale price for generic tigecycline is far below the brand price of $300–$400 per vial. Data from DrugPatentWatch.com shows continued active generic competition and ongoing litigation over secondary patents.